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We have determined the precise chromosomal loca- 
tion, the exon structure,  and  the  expression  pattern of 
CGM2, a  member  of the carcinoembryonic antigen (CEA) 
gene  family. CGM2  cDNA was  amplified by reverse  tran- 
scription-polymerase  chain reaction (RTPCR)  from the 
colon  adenocarcinoma cell line, LS174T. A defective  exon 
is missing from this cDNA clone, leading to a  novel  do- 
main  organization  for the human CEA family  with  two 
immunoglobulin-like  domains.  The  derived  C-terminal 
domain  predicts  that the CGM2 protein is membrane- 
bound  through  a  glycosyl  phosphatidylinositol  anchor. 
RT/PCR analyses identified CGM2 transcripts  in  muci- 
nous  ovarian  and  colonic  adenocarcinomas as well as in 
adjacent colonic tissue, but not in other  tumors  includ- 
ing leukocytes from six chronic  myeloid  leukemia  pa- 
tients. Thus,  unlike  several  other  family  members, CGM2 
is not  expressed in granulocytes  but reveals a more  CEA- 
like expression  pattern.  Northern  blot analyses identi- 
fied a  2.5-kilobase CGM2 mRNA that is strongly  down- 
regulated in colonic adenocarcinomas compared with 
adjacent colonic mucosa, suggesting a possible tumor 
suppressor function. In addition, a 3.2-kilobase tran- 
script  was  observed in a  number of colon  tumors  that is 
not detectable in normal colonic tissue. This mRNA 
species could represent a tumor-specific CGM2 splice 
variant. 
The carcinoembryonic antigen (CEA)’ gene family contains 
29 genes (11, which are densely packed within a 1.2-megabase 
region on the long arm of chromosome 19 (2). The CEA family 
belongs to the immunoglobulin superfamily (3). The derived 
protein structures show that CEA family members  consist of 
one N-terminal, immunoglobulin variable (1gV)-like domain (N 
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domain), followed by zero, two, three, four, or six immunoglobu- 
lin constant (1gC)-like domains of subtype A or B (reviewed in 
Ref. 4). Sequence comparisons allow the division of CEA-re- 
lated genes into two main subgroups, one that encodes CEA 
and  its classical cross-reacting antigens  and  the second con- 
taining 11 genes that encode the pregnancy-specific glycopro- 
teins (PSG). CEA subgroup proteins are mostly membrane- 
bound, either  through a glycosyl phosphatidylinositol (GPI)  tail 
or as integral membrane proteins with transmembrane and 
cytoplasmic domains.  PSG molecules are directly  secreted from 
the cell and possess only very short  C-terminal domains. The 
CEA subgroup  contains  12  genes, of which five apparently rep- 
resent pseudogenes (1, 5 ) .  As far as they  have been  analyzed, 
the  other seven  potentially  active genes of this  subgroup  have 
open reading  frames,  and  transcripts  have been  identified for 
six members, i.e. for CEA,  the nonspecific cross-reacting anti- 
gen (NCA), biliary glycoprotein (BGP) ,  and CEA gene  family 
members 1, 6,  and 7 (CGM1, CGMG, and CGM7 (summarized 
in Ref. 4). The  remaining gene (CGMZ)  has so far only been 
partially characterized at the genomic level (6). 
Although  CEA-related  genes are very similar at  the sequence 
level, they show variable expression patterns. CEA itself is 
mainly  expressed in different epithelial cells, especially those 
lining  the  gastrointestinal  tract (7). Much higher CEA concen- 
trations  are often found in  a variety of carcinomas, e.g. colonic, 
lung,  and  breast adenocarcinomas,  where CEA is of great clin- 
ical value as a tumor  marker (8). The closely related NCA-50190 
is often coexpressed with CEAin a number of tumors (4,9). The 
larger glycosylation variant NCA-90 is also present in granu- 
locytes (10) where no CEA is found.  A number of other CEA- 
related molecules are coexpressed in granulocytes, e.g. the 
product of CGMG, NCA-95 ( l l ) ,  BGP, and  CGMl (12-15). BGP 
is also  expressed in  epithelia of the bile canaliculi (16). Inter- 
estingly, it was  recently shown that  the expression of the  hu- 
man B G P  gene, as well as of its  murine homologue B g p l ,  is 
down-regulated in colonic tumors as compared with the  adja- 
cent colonic mucosa, and the levels of rat BGP homologues 
(cell-CAM105) are reduced in hepatocellular  carcinomas (17- 
19). On the  other  hand,  the N C A  gene is up-regulated  whereas 
the CEA  mRNA steady state levels stay more or  less  the  same 
in colorectal cancers (17). I t  could be shown in vitro that CEA, 
NCA, and BGP are capable of mediating cell adhesion (20-22) 
so that their deregulation, as found for other cell adhesion 
molecules (23, 24), could play  a causal role during  tumor de- 
velopment, e.g. BGP down-regulation could facilitate tumor cell 
release from their  normal  environment. 
As a prerequisite for the cDNA cloning strategy that we 
adopted, we describe here  the genomic organization and exon 
sequencing of the CGM2 gene. We have shown that  this  last 
known,  potentially  expressible  member of the CEA subgroup is 
in fact  expressed. Internal  primers specific for this gene have 
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FIG. 1. Fine  mapping of the CGMZICEAINCA gene  region. Only the CGM2, CEA, and NCA genes are shown.  Their  relative  positions  within 
the CEA gene  cluster  have  been  described  elsewhere (5). The  upper  part  reveals  the  EcoRI ( E )  restriction  enzyme  sites  over  this  gene  region. 
Rare-cutting  restriction  enzyme  sites for MluI  (M)  and Sac11 (Sc) as well as the PstI ( P )  and SstI ( S )  sites  relevant for probe preparation  are  also 
included.  The  gene  names  are  written above together  with  arrows  that  indicate  directions of transcription.  The  exons  are  depicted  as blocks. 
Filled-in blocks with  letters below indicate  exons  encoding  the  5'-untranslated  region  and  most of the  leader  sequence (L) ,  the  N-terminal IgV-like 
pseudo-B exon (B') of CGM2; the open and  stippled boxes show putative NCA-like 3"untranslated  region  exons ("NCA3") in  the CGM2 and CEA 
domain ( N ) ,  IgC-like domains (A and B ) ,  the hydrophobic membrane  domain (M), and a 3"untranslated  region (3'). The  striped box indicates  the 
genes, respectively, whereby the former has only been  mapped  through  hybridization  to  the  indicated EcoRI DNA fragment.  The  position of 
terminal DNA probes  from cosmid clone cosCEAl(25)  and from h39.2 (37) that co-hybridize with  the  same  13  kb EcoRI DNA fragment  in  digested 
genomic DNA are shown below this  map.  Similarly,  the 527-bp SstIISacII fragment from cosCEAl  and  the 667-bp EcoRIIPstI fragment from the 
NCA gene,  which  were  used  to  isolate cosCEA2 and cosCGM2, respectively, are shown  (probes).  The  central  part  shows  the  positions  and  sizes of 
four  overlapping cosmid clones  (cosCEAl, cosCEA2, cosCGM2, and cosCGM2a) and of the NCA gene-containing A clone ,439.2 with  respect to  this 
region.  The lower part  reveals  individual  restriction  enzyme  maps of clone cosCGM2a with  the  exons from the CGM2 gene  shown below. 
been  used  to  assay for CGM2 transcripts  in RNAs from a large 
number and variety of tumors and some normal tissues by 
reverse transcription followed by polymerase chain reaction 
(RTIPCR). With the knowledge that  other members of the CEA 
subgroup  are  deregulated  during  tumorigenesis, we have de- 
termined  the  steady state levels of CGMZ transcripts  in colonic 
tumors  in comparison  with adjacent mucosa by Northern blot 
analyses. 
EXPERIMENTAL PROCEDURES 
Cosmid Isolation and Analysis-The cosmid library  used  for  screen- 
ing  was  obtained  from W. Lindenmaier  (Gesellschaft  fur Biotechnolo- 
gische Forschung, Braunschweig, Germany) and has been described 
elsewhere  (25). Specific probes  (see  "Results")  were  hybridized at high 
stringency  washing  conditions, i.e. 0.1 x SSPE, 0.1% SDS at 65 "C (1 x 
SSPE  is  0.18 M NaCl, 10 mM sodium  phosphate,  pH 7.4,l  mM EDTA), to 
isolate  clones cosCEA2 and cosCGM2. Clone cosCGM2a was  isolated 
employing two degenerate oligonucleotides as described before (26). 
Genes  contained in cosmid clones  overlapping the CEA gene  locus  were 
identified by PCR amplification of regions  within the  N-terminal do- 
mains using oligonucleotides P C R C E A a l l 5 ' ( 5 ' - G C G C A G A G -  
GGGAAGGAGGT-3') and PCRCEAall3' (5"GGAATTCATCAGCA- 
GGGATGCATTGG-3') as primers.  These oligonucleotides were  derived 
from sequences that  are conserved for all  known  members of the CEA 
subgroup.  In  comparison  with CGM2 (6 )  one and two  mismatches  are 
found, respectively. EcoRI linkers  were  included (bold print). PCR was 
performed  using 1-10 ng of nonlinearized cosmid DNA over  30 cycles 
using a bio-med Thermocycler 60 (Bachhofer, Reutlingen, Germany), 
basically  according to  Sambrook  et al. (271, with  the following modifi- 
cations: the  melting  temperature  was 93 "C, and  annealing  was for 15 
s at 56 "C. Amplified fragments  were  subcloned  into  a  Bluescript  pha- 
gemid vector (Stratagene,  Heidelberg,  Germany)  as  blunt-ended  frag- 
ments  into  the EcoRV site. DNA from these  double-stranded  templates 
was sequenced by the dideoxy chain termination method (28) with 
universal  primers  using a kit from Pharmacia  (Freiburg,  Germany).  A 
series of four oligonucleotides, corresponding to  different  exons of  CEA 
were  used  to  identify homologous regions within the CGM2 gene by 
hybridization, following multiple  restriction  enzyme  digestions of 
cosCGM2a, as recently  described  (26). Those regions  exhibiting homol- 
ogy were  subcloned  into  pUC18 for double-stranded  sequencing  in  both 
directions. Restriction enzyme mapping was achieved after complete 
digestion of the cosmids with  either  a  single  enzyme  or double diges- 
tions  in  different  combinations. 
cDNA Cloning-Based on sequence data ofCGM2, two oligonucleotide 
primers  were  synthesized from the  leader (CGM2-L, B'-AAGGT"GTC- 
CATACAGAGTGTGCATT-3') and  the  3"untranslated  regions (CGM2- 
3'UT, 5'-AGATCTAGAAATYRAGAAACTAAACTACACCAA-3') t o  clone CGM2 
transcripts  from  the LS174T colon adenocarcinoma cell line  (American 
Qpe Culture Collection, Rockville, MD) by RTPCR. Total RNA was ex- 
tracted  using  the  guanidinium  thiocyanate  method, foll wed by pelleting 
through  a  cesium  chloride  cushion  (29). For reverse  transcription, 5 pg 
of total RNA was  used  as  a  template  using  random  hexamer  primers at 
42 "C in 15 pl  with a kit  and  the protocol from  Pharmacia. Following this 
step, 3 p1  of the  mixture  were  taken,  and  the CGM2 primers  were  added 
(50 pmol each)  along  with  0.5  unit of Taq polymerase  (Promega,  Hei- 
delberg,  Germany),  and  the volume was  made  up  to 10 pl  with  water. 
Thirty-five  amplification cycles were  carried  out at an annealing  tem- 
perature of 55 "C (72  s/step).  The  obtained  product (5pl)  was  used as a 
template for a second amplification  step  using an extended 5'-oligonu- 
cleotide (CGM2-PCRB', 5'-CCATGGGTTCCCCTTCAGCCTGTCCATA- 
CAGAGTGTGCA-3') to encompass the translational start codon, to- 
gether  with  the CGM2-3'UT primer, at  an  annealing  temperature of 
52 "C over  30 cycles. After  phosphorylation, the product  was  blunt-end 
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TyrValPheS 
276 ... MTGTCCCCT 
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254 ... ACAGTCCGTG 
127 ... CGGAAGAGTG 
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Intron Exon 
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gfgagtgga9gacttcctgggagt ... 880 . . . a c t g a t g t t c t c t c c c c c t c c t ~  CCTCGCTTTTT..  363 N 
LaSerLeuLeu 
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FIG. 2. Nucleotide  sequences of exodintron borders of the CGMZ gene (A) and the  nonspliceable B exon (B) .  Capital letters indicate 
coding regions with the amino acid sequences below. Intron sequences are shown in lower case letters. Splice donor and acceptor sites are 
underlined, and the degenerate splice  acceptor  for the nonspliceable B exon ($B) is shaded. Abbreviations  for the exons are  as in the legend to Fig. 
1. In (B) ,  the mutated base (A-  G) at  the splice  acceptor site of the pseudo-B  exon ($B) is additionally indicated with an arrowhead. Dashes reveal 
deleted nucleotides after alignment with the B1 introdexon region of the CEA gene (25). 
ligated into pUClS using the Pharmacia Sureclone kit, following the 
manufacturer’s instructions, and sequenced in both orientations. DNA 
sequence comparisons were carried out using the program “Clustal”(PC- 
gene, IntelliGenetics, Inc., Mountain View,  CA),  which is based on av- 
erage linkage cluster analysis (30) and was used to construct dendro- 
grams. 
RNA Isolation, RTIPCR Assay, and Northern Blot Analyses-Total 
RNA was isolated either from deep frozen normal tissues, primary 
brain, breast, ovarian, and colonic tumors as well as white blood cells 
from  chronic  myeloid leukemia patients or from human tumors propa- 
gated in nude mice as described  previously (9). Its integrity was first 
tested in an RTPCR  assay using primers to identify p-actin and/or c-abl 
transcripts. CGM2 transcripts were then assayed, also using an RT/ 
PCR system. The primers used for amplification had at least five  mis- 
matches to all other members of the CEA gene family. The 5“primer 
from the M domain (CGM2-M, 5’-CTGCAGCGGTTCCAGCTGAGAG- 
was the CGM2-L oligonucleotide (see above), and the 3”primer was 
GTCAGGT-3‘ (see Fig. 3)). Amplification  was carried out over  30 or 40 
cycles with an annealing temperature of 56 “C (15 s) and denaturation 
at 94 “C (15 s), using 50 pmol of each each primer. Plasmid pCGM2 
containing the full length CGMZ  cDNA was used as a positive  control, 
and  the specificity  was  confirmed using 5 ng of plasmid DNA containing 
cDNA of other CEA subgroup members as templates. Water replaced 
RNA in the negative control. For Northern blot analyses, fresh tissue 
samples were obtained from  colon cancer patients during surgery. From 
each patient, both tumor and adjacent colonic mucosa tissue samples 
were obtained and processed separately, essentially as described re- 
cently (17). From  each sample, 15 pg of total RNA were analyzed by 
hybridization with the complete CGMZ cDNA as a probe  according to 
standard procedures. Final stringency washings were carried out twice 
at 65 “C for  30  min in 0.1 x SSPE, 0.1% SDS. 
RESULTS 
Isolation of a  Cosmid Clone and Determination of the Exon 
Structure of the CGM2 Gene-In order to gain sequence infor- 
mation from the complete  coding  region of the  last known  mem- 
ber of the CEA subgroup that is potentially transcriptionally 
active, a cosmid  clone containing the CGM2 gene (cosCGM2a) 
was isolated from the same human genomic library using the 
same method of isolation as  that described for the CEA gene 
(31). In addition to identifying a CEA-containing cosmid, the 
oligonucleotide probes hybridized less intensely to a cosmid 
containing the  entire coding and flanking regions of the CGM2 
gene as determined through partial, double-stranded DNA se- 
quencing of restriction endonuclease digested fragments and 
comparison with the  partial CGM2 gene sequence published 
elsewhere (6). The organization of the CGMZ gene was deter- 
mined by digestion of the cosmid with a  series of restriction 
enzymes and hybridization with oligonucleotides  from different 
domains of the CEA gene (26). The results suggest an exon 
arrangement analogous to that of the NCA gene (Figs. 1 and 
2 A ) .  Sequencing of each homologous  region revealed that  the 
first exon  codes  for 21 amino acids of the leader sequence ( L )  
and  the second encodes the remaining 13 plus the entire N- 
terminal domain ( N ) .  The third exon  encodes an IgC-like do- 
main of subtype A (A) ;  the fourth exon reveals homology to  the 
subtype B IgC-like domains ( B )  of the NCA gene but has a 
degenerate splice acceptor site, where the requisite  A is substi- 
tuted by a G (Fig. 2). Within the B exon  two deletions of three 
nucleotides each are followed by a single deletion (Fig. Z B )  
when compared with the CEA gene B1 exon (25). This single 
deletion (nucleotide position 409 in Ref. 32) leads to a frame- 
shift that is quickly followed  by a stop codon, Taken together, 
these data suggest that  this is a pseudo-B  exon. The final exon 
encodes a 30 amino acid, hydrophobic membrane (M) domain 
whose sequence similarity to corresponding regions of CEA, 
NCA-50/90, and NCA-95 (4) suggest its posttranslational sub- 
stitution by a glycosyl phosphatidylinositol tail. In analogy to 
the corresponding exon of the CEA gene, 39 nucleotides of the 
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1 CCATGGGTTCCCCTTCAGCCTCTCCATACAGAGTGTGCATTCCCTGGCAGGGGCTCCTGCTCACAGCCTCGCTTTTAACCTTCTGGAACCTGCCAAACAGTGCCCAGACCAATATTGATG 
- r , ”  
MetGlySerProSerAlaCysProTyrArgValCysIleProTrpCLnGLyLeuLeuLeuThrAlaSerLeuLeuThrPheTr~snLeuProAsnSerALaGlnThrAsntleAspVal 
121 TCGTGCCGT~CAATGTCGCAGMGGGAAGGAGGTCCTTC~AGTAGTCCA~AATGAGTCCCAGAATCTTTATGGCTACAACTGGTACAAAGGGGAAAGGG~GCATGCCMCTATCGMTTA 
241 ~AGGATATG~AAAA~~~ATAAGTCAAGMMTGCCCC~GGGCCCGCACACAACGGTCGAGAGACAATATIICCCCAATGGAACCCTGCTGATCCAGAACG~TACCCACM~GACGCAGGA~ 
361 TCTATACCC~ACACGTTATAAAAGAAMTCTTGTGAATGAAGAAGTAACCAGACAATTC~ACGTATTCTCGGAGCCACCCMGCCCTCCATCACCAGCMCMCTTCM~CCGGTGGAG~ 
ValProPheAsnVaLAlaGluGlyLysGluValLeuLeuValValHis~~luSerGlnAsnLeuTyrGlyTyrAsnTrpTyrLysGlyGluArgValHisAlaAsnTyrArgt LeILe 
GlyTyrValLysM91 1eSerGLnGluAsnAlaProGlyProAlaHisAsnG~yArgGluThrI LeTyrPro&$mGlyThrLeuLeuI . ,.... A,. LeClnkWfValThrHisAsnAspAlaGlyPhe 
TyrThrLeuHisValIleLysGLuAsnLeuValAsnGLuGluValThrArgGLnPheTyrValPheSerGluProProLysProSerIleThrSerAsnAsnPheAsnProValGluAsn 
LysAspI 1eValValLeuThrCysGlnProGluThrGL~~~ThrThrTyrLeuTrpTrpValAs~~~lnSerLeuLeuValSerProArgLeuLeuLeuSerThrAs~~rgThr 
481 ACAMGATATTGTGGTTTTAACCTGTCAACCTGAGACTCAGA.ACACAACCTACCTGTGGTGGGTMACAATCAGAGCCTCCTGGTCAGTCCCAGGCTGCTGCTCTCCACTGACAACAGGA 
601 CCCTCGTTCTACTCAGCGCCACAAAGAATGACATAGGACCCTATGAATGTGAAATACAGMCCCAGTGGGTGCCAGCCGCAGTGACCCAGTCACCCTGAATGTCCGCTATGAGTCAGTAC 
P ”  
LeuValLeuLeuSerAlaThrLysAsnAspIleGlyProTyrGluCysGluIleGlnAsnProValGlyAlaSerArgSerAspProVa~ThrLeuAsnValArgTyrGluSerValGln 
721 MGCAAGTTCACCTGACCTCTCAGCTGGGACCGCTGTCAGCATCATGATTGGAGTACTGGCTGGGATGGCTCTGATATAGCAGCCTTGGTG 
AlaSerSerProAspLeuSerA\aG~yThrALaValSerl~eMetIleGlyValLeuA~aGlyMetAlaLeuILe*** 
B 
L N A M 
34 109 92 30 
FIG. 3. Nucleotide  and  deduced  amino  acid  sequence (A) and  deduced  domain  organization ( B )  of the CGM2 cDNA A, nucleotides 
legend to Fig. 1. The stop codon is depicted by three asterisks. The positions of the primers used for RTPCR screening of CGM2 transcripts are 
are numbered at the left. Domain borders were  deduced  from the exon borders and are indicated by arrows. Domain abbreviations are  as in  the 
ouerlined in the sequence. Putative N-glycosylation sites are shaded. B, the deduced  domain organization of the CGM2 preprotein is depicted with 
differentially shaded boxes. The number of amino acids is listed below each  domain. Cystein (C) positions are indicated within the  A domain. 
Abbreviations for the domains are  as in the legend to Fig. 1. 
3‘-untranslated region and an intact splice  donor site follow the 
“domain. 
Cloning of CGM2 cDNA-In the search for putative CGM2 
transcripts, RT/PCR was performed on total RNA from the 
colon adenocarcinoma cell line LS174T using CGM2-specific 
oligonucleotides based on  genomic sequences from the leader 
(CGM2-L) and from the 3”untranslated regions  (CGM2-3’UT), 
yielding an 819-bp amplification product. This cell line was 
originally chosen because it  is known to express various mem- 
bers of the CEA subgroup (33). A second amplification step was 
then carried out using the extended 5’-primer, CGMS-PCR5’ 
with CGM2-3’UT to generate  a full length CGMS  cDNA clone 
with respect to  the coding region. Direct amplification from 
RNA with this primer combination  proved to  be unsuccessful. 
The  resulting  fragment  had  a size of 833 bp and was cloned for 
sequencing. The DNA and derived amino acid sequence, along 
with the domain structure,  are shown in Fig. 3. Compared with 
the genomic sequence and the published N-domain exon se- 
quence, two  nucleotide substitutions  are found at positions 341 
(C + T)  and 749 (A + G) of the cDNA sequence, which do not 
lead to  amino acid changes. The translated region consists of 
798 nucleotides including the stop codon and encodes a  puta- 
tive protein with 265 amino acids that would yield a polypep- 
tide with a relative molecular mass of 25,689 after removal of 
the 34-amino  acid leader sequence. Seven potential N-glycosy- 
lation sites are present,  and assuming a carbohydrate mass of 
3000/site the expected size of the mature CGMS protein would 
be approximately 47,000 with the “domain or 44,000 after  its 
removal. The domain structure, derived after sequence com- 
parisons with other CEA-related molecules, reveals that  the 
CGM2 protein has only  one  immunoglobulin C2 set domain (34) 
of subtype A.  As expected  from the size of the PCR product, no 
B domain is present. Amino acid sequence comparisons were 
carried out with other members of the CEA family for the 
N-terminal domain and A domain (data not shown). In both 
cases, CGMS is more  closely related to  the CEAthan to the PSG 
subgroup. Within the CEA subgroup, however, it  is  the least 
similar member apart from the CEA subgroup members CGM7 
(N domain  sequence comparisons) and the BGP A2 domain (A 
domain sequence comparisons), which segregate alone. 
Search for CGM2 IFanscripts in Various Normal Tissues and 
!lLmors-Awide range search was carried out to determine the 
expression pattern of the CGM2 gene in  a large number of 
tumors and  a small collection of normal tissues. To achieve this, 
the specificity of the PCR-primers was first tested using cDNAs 
for various CEA family members as templates. All cDNAs 
tested (Fig. 4A) were negative, apart from CGMS cDNA that 
yielded a 732-bp amplification product (Fig. 4C). 118 human 
tumor samples of  25 different tumor types, 4 tumor cell lines, 5 
normal colonic mucosae (adjacent to tumors), 1 placenta, and 1 
amnion tissue sample have been analyzed for the expression of 
CGM2 at the transcriptional level (Fig. 4; data not shown). 8 of 
12 ovarian mucinous adenocarcinomas, 5 of 5 normal colonic 
mucosae, 5 of 7 colonic adenocarcinomas, and the colon adeno- 
carcinoma cell line LS174T revealed amplification products of 
the expected size. The following other tumors were all negative 
for CGM2 transcripts: 55 ductal and 6 lobular breast carcino- 
mas; 16 other breast tumors (including comedo, intraductal, 
mucinous, medullar, and anaplastic carcinomas as well as  sar- 
comas); 2 meningiomas, 4 mucinous, 3 serous, and 1 endometri- 
oid ovarian carcinoma; 2 colorectal  adenocarcinomas; the leu- 
kocytes from 6 chronic  myeloid leukemia patients; 5 lung 
tumors (2 small cell, 1 large cell, 1 adenocarcinoma, and 1 
squamous epithelial carcinoma); single gall bladder, stomach, 
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i 
1*'1(;. 4 .  Analys is  of CGM2 e x p r e s s i o n  in v a r i o u s  t i s s u e s  and 
t u m o r s  using HTIPCR. RSAs rs t ractcd from  tumors,  tumor  metas- 
tases 1 / r r m .  m d .  I. and  normal  t issurs IR and C 1 and  to test specificity. 
cDNAs  from  different  CRA  family memhers f A  1 were  used as templates. 
An amplification product with the expected size of 732 hp is clearly 
visible  in somr Ianrs.  Amplification  was  carried  out  over 80 ( A  and C )  
or 40 cyclrs 113). 
kidney,  testis,  and  pancreas  tumors;  and 1 colonic (SW403) and 
1 pancreatic  (ASPC-1)  adenocarcinoma cell line.  The  placenta 
and  amnion  tissues  were also negative. 
CGM2 Genr Exprrssion in  Colonic Adenocarcinomas and 
Adjacent Colonic Mrrcosn-As the  expression of some  members 
of the CEA subgroup is known to be deregulated in colonic 
adenocarcinomas.  we  decided  to  determine  quantitatively 
CGM2 expression at the transcriptional level from colon tu- 
mors  with  respect  to  the  adjacent  mucosa.  Northern  blot  hy- 
bridization  with  the CGMB cDNA probe  revealed  an  mRNA of 
2.5 kb  in  normal  mucosae  after  high  stringency  washing  steps. 
Cross-hybridization  to  other  members of the  CEA  gene  family 
was  not  observed,  since  no  additional  bands  were  detected  (Fig. 
SA). The mRNA species hybridizing with the CGM2 probe is 
down-regulated in all 11 tumors  analyzed  compared  with  the 
adjacent colon mucosae  (Fig.  5R).  This  finding  excludes  cross- 
hybridization of the  probe  used  with NCA transcripts,  which 
are  also  2.5  kh  in  size (35) ,  as the  latter  are  up-regulated  in 
colonic tumors (17). Since carcinomas are known to contain 
variahle  proportions of tumor  stromal  tissue,  we  used a cyto- 
keratin 18 probe  to  correct for the  fraction of epithelial  mRNA 
A 1 1  N I  17 N7 13  N3 TJ NJ 15 N5 T f i  N6 
3 2 ~  
- 
7 5". CGM-2 
B 
c y t  18 
- c y t  18 
normal tumor 
FIG. 5. N o r t h e r n   b l o t   a n a l y s e s  to d e t e r m i n e  the s t e a d y  state 
leve ls  of CGM2 m R N A  in c o l o n i c   a d e n o c a r c i n o m a s  and a d j n c e n t  
co lon ic   mucosae .  A .  RNA was isolatrd from co lon~r   :~d rnoca r r~nnm;~s  
( T I  or adjacent  mucosa f.\') of 11 patwnts.  After  rlcrtrophorrttr w p a -  
ration  and  transfer,  the  membrane was hyhridized  with  a C(;\lB-spr- 
ci tk   and a cytokeratin 18-specific (C.vt 181 prohr  and  washed a t  high 
stringency  conditions.  Sizes of the  hyhridizing simals are   ~ndica t rd  a t  
the  lrf/ in kh. R ,  histograms  showing  the  relative steady .statr lrvrls of 
the 2.5-kb transcript in tumors and adjacent mucnsa(* (normal  1. The 
relative  CGM2  mRSAsteady  state  Irvels an. expressed as percrntagrs. 
with  the  normal  colonic mucosa srt at 100'7. Standard  tlrviations  arc 
indicated  by ham. 
in  these  samples  by  calculation of tumor-to-normal  ratios. For 
this  purpose,  the  Northern blot signals  were  quantified hy den- 
sitometry  from  the  integer  over  the  mRNA  hands  in  the  auto- 
radiograms for both CGM2 and c-ytokeratin 18. The rrlativr 
expression  (RE) of CGMB in  the  tumors  (RE(CG1\12-tu1)  with 
respect to normal expression was then calculated using thr 
formula,  RE(CGM2-tu) = (c-yt,n) + c.yt(tu), x fCGM2ltu1 + 
CGM2(n)),  where  cyt  and CGMB are the expression levels of 
cytokeratin 18 and  CGM2  mRNA,  in  normal f n )  or tumor   ( tu )  
tissues, respectively. From the eleven patients invrstigatrd, 
RNA samples of one did not give a positive cytokerntin 18 
signal in the Northern blot analysis and had to hr rxcludrd 
from the  evaluation.  For  the  remaining  ten  patients,  thr rrla- 
tive  cytokeratin 18 corrected  expression of CGl12  was 5 2 2.2 
in normal colonic mucosa and only 0.5 2 0.7 in thr tumors 
(Fig. 5 B ) .  
Resides finding a strong down-regulation of CGM2 mRNA 
steady  state  levels,  the  majority of tumors  that  still  exhihited a 
residual  expression  also  showed  an  additional  mRNA  species of 
3.2 kh of approximately  the  same  intensity  as  the  2.5-kh  mRNA 
(Fig. 5A ). This  larger  mRNA  species  was  found  exclusively in 
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tumors,  although  the  general CGM2  mRNA steady  state level 
was low. Cross-hybridization to CEA or related mRNA species 
of a similar size can  be  disregarded, since the probe did not 
detect CEA mRNA in  the  normal  tissue  that is known to ex- 
press  substantial levels of CEA transcripts (32). 
Isolation of CGM2 Cosmid Clones That Overlap the CEA 
Gene  Locus-RTIPCR analyses revealed that  the CGM2 gene is 
often coexpressed with the CEA and NCA genes (data not 
shown). As it has been reported that these three genes are 
directly adjacent  to  each  other on the long arm of chromosome 
19  (36), we decided to  extend  the fine restriction enzyme map 
encompassing these genes as a basis for future  investigations 
to locate and identify putative common, cis-regulatory ele- 
ments.  In  order to  isolate clones overlapping the CEA (25, 26) 
and NCA (37)  genes, we used a CEA gene-specific probe (5’- 
CEA) from the 5”region of a genomic cosmid clone cosCEAl 
(25). This 527-bp SstIISacII  fragment  is located at  nucleotides 
-1769 to -1242 upstream from the  translational  start  site of 
the CEA gene and  was  used  to  screen a cosmid library  under 
high stringency washing conditions. Its specificity under  these 
conditions has been described elsewhere (5). Apart from the 
original CEA clone (cosCEAl),  a second clone was also isolated 
(cosCEA2). Hybridization with a 220-bp PstUPstI probe from 
the  5”untranslated region and  part of the  leader of a NCA 
cDNA clone, pNCAl (38) under low stringency washing condi- 
tions  (2 x SSPE, 1% SDS at 65 “C), revealed two hybridizing 
SstI  fragments of 7.7 and 2.7 kb  in cosCEA2, indicating  the 
presence of an  N-terminal domain exon from  a second CEA- 
related gene within  this clone. The 2.7-kb fragment is compa- 
rable  in size to that  determined elsewhere for the CGM2 gene 
(39), and indeed the presence of CGM2  close to  the CEA gene is 
supported by a long range  restriction enzyme map  and  analyses 
of groups of overlapping clones (5, 36). This was further sup- 
ported by identifying the two SacII  as well as  the  MluI  restric- 
tion  enzyme sites predicted to exist in between these two genes 
within clone cosCEA2 (Fig. 1). The  final proof that  this 
clone also contains  the  N-terminal domain exon of the CGM2 
gene was provided by PCR analyses using the PCRCEAall 
oligonucleotide primers  ( ee  “Experimental Procedures”). 
The sequence of a subcloned PCR  amplification  product 
from this clone was  identical  to  the CGM2 sequence  published 
elsewhere (6). 
Another cosmid clone (cosCGM2) was also shown by PCR 
and DNA sequencing to  contain  the  N-terminal domain exon of 
the CGM2 gene. This clone was originally isolated from the 
same cosmid library  with a 667-bp EcoRUPstI fragment, which 
is located at nucleotides -1247 to -580 upstream of the NCA 
gene translational start site (37). Restriction  endonuclease di- 
gestion  revealed  a number of fragments that are common to  
cosCEA2, and cosCGM2 is also  digestible with MluI. However, 
cosCGM2 was found not  to  contain  the  SacII  sites  present  in 
cosCEAl and cosCEA2. Restriction  enzyme  mapping of these 
clones confirmed the degrees of overlap for these  three clones 
(Fig. 1). 
In a previous  publication we were  able to show that  the gene 
encoding NCA is located  immediately downstream of the CEA 
gene (5). As we have genomic clones containing the  total CEA 
gene (25,261  as well as a clone containing the start of the NCA 
gene  (37) at our disposal, we attempted  to confirm linkage at  
the fine structural level. Based on the  assumption  that  these 
two genes are in a head-to-tail orientation, DNA fragments 
from the  upstream region of the NCA clone h39.2 (7.6-kb ter- 
minal EcoRI fragment (see Ref. 37)) and  the downstream region 
of the CEA clone, cosCEAl (0.65-kb terminal EcoRI fragment 
(see Ref. 25),  hybridized  with the  same 13-kb EcoRI genomic 
DNA fragment  in  the presence of unlabeled human genomic 
DNA to  saturate  repetitive sequences in  the probes (data  not 
shown). The complete EcoRI restriction enzyme map covering 
the CGM2 f CEA f NCA genes is shown in Fig. 1 together  with 
other  restriction enzyme sites for the CGMZ locus. 
The restriction enzyme map including the CEA and NCA 
gene loci show that  the CGM2 gene has  an  inverted  orientation 
on the chromosome. It  is situated approximately 20 kb up- 
stream of the CEA gene, the  same  distance  that  separates  the 
CEA and NCA genes. Hybridization analyses with a 1.5-kb 
EcoRI probe from the  3”untranslated region of the NCA  cDNA 
clone 9 (35) reveal  similar sequences in  the 3“region of the 
CGM2 gene. This  indicates  that  the whole 3’-region is  similar 
in its basic structure to that of the CEA gene (25). 
DISCUSSION 
Through chromosome walking, we have isolated cosmid 
clones and  carried  out  detailed  restriction endonuclease map- 
ping and sequence analyses to  determine  the  structure of the 
CEA-related CGM2 gene.  These  investigations verify its close 
linkage to  the CEA and NCA genes, as also shown elsewhere by 
analyses of groups of overlapping clones (36) and allow exact 
determination of the  distances between the  three genes. In  the 
long range map, these three genes have been located in be- 
tween the CGM7 and CGMl  genes, within  the CEA subgroup 
cluster closest to the centromere, as reported elsewhere (5). 
CGM2 contains five exons covering the coding region, whereby 
exon four represents a nonspliceable B-domain exon, with a 
degenerate splice acceptor site. A single nucleotide deletion 
within  this exon causes  a frameshift  and soon leads  to a  stop 
codon. Indeed, this nonspliceable B-domain exon is missing in 
the CGMS cDNA clone that was amplified by RTIPCR from 
LS174T cell RNA. Products of an identical size from other RNA 
sources (Fig. 4) indicate the same domain organization. The 
predicted structure of the CGMB protein is  unique  within  the 
human CEA family (41, with  the  omnipresent  leader (L) and 
N-terminal, IgV-like domain (N domain), followed  by just one 
IgC-like domain of subtype A. Other members have  either no 
IgC-like domains (CGM1 and CGM7), or at  least wo (e.g.  NCA, 
CGM6 and BGPb, d, h,  and 1 splice variants (reviewed in Ref. 
4)). It  remains  to be tested  as  to  whether  this difference has  any 
functional  implications or not. The  short hydrophobic domain 
(M) shows homology to corresponding regions of CEA, NCA-SO/ 
90, and NCA-95 that  are  posttranslationally replaced by a gly- 
cosyl phosphatidylinositol moiety, which anchors  the molecules 
into  the  membrane. Therefore, a similar modification may be 
expected for the CGMB product. Although distantly  related  to 
the CEA subgroup  members, the derived CGMS protein can be 
placed within  this subgroup. This affiliation was expected from 
the position of the gene within  the CEA subgroup  gene cluster 
on chromosome 19 (5). The close linkage of CEA gene family 
members, together with their highly conserved DNA sequences 
and basic domain structures (41, suggests that they have 
evolved recently by unequal crossing over. Interestingly,  inver- 
sions must also have occurred to  explain the head-to-head 
genomic arrangement of  CGM2 and CEA. 
In order to study the expression pattern of  CGM2 at a 
broader level, the RTIPCR method was utilized  because it  al- 
lows unequivocal differentiation of CGMB transcripts.  The ex- 
pression studies  were mainly carried  out on tumors because of 
limited  availability of normal human tissues.  Although CGMB 
expression is down-regulated in colonic tumors (Fig. 51, the 
high sensitivity of the RTIPCR method allowed discernment of 
transcripts  there,  and a comparison with the expression pat- 
tern of other CEA family members could still be made. The 
CGMB expression pattern found is most similar  to  that of CEA, 
i.e. expression in  normal  human colon as well as colonic and 
mucinous ovarian adenocarcinomas (9,32). No expression was 
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found in leukocytes of chronic myeloid leukemia  patients, al- 
though  it is known that cells of the granulocyte  lineage  express 
most of the NCA species but not CEA  (11-15), or in  placenta 
that expresses most PSGs (40). However, the expression of 
CGMB is more  limited than  that of CEA because a number of 
tumors known to express CEA transcripts, e.g. 60% of 71  breast 
tumors examined: were all negative for CGMB transcripts.  In 
the RNAs investigated, when active, the CGM2 gene is always 
coexpressed with  the CEA and NCA genes, which together  with 
their close genomic locations indicates  that common or closely 
related regulatory elements may be responsible for coordinat- 
ing  this. Indeed, such  an  element for regulating  the CGM2 and 
CEA genes could be located in  their common  20- kb  upstream 
region, as  they  are  in a head-to-head orientation  to each other 
(Fig. 1). 
A regulated coexpression of different  members of the CEA 
family may  have  functional  implications. Coexpression within 
the  same celI and  their presence on  the cell membrane are 
reminiscent of other members of the immunoglobulin super- 
family that functionally interact forming, e.g. the T-cell and 
B-cell receptor complexes (41). In a similar  manner, CEAfamily 
members could build complexes on the cell surface. Preliminary 
data do indeed  indicate that CEA family members form com- 
plexes on the surface of  neutrophil^.^ CEA, NCA-50/90,  NCA- 
95, and possibly CGMB are GPI-linked to  the cell membrane 
(11,42,43,  and  results  presented h re).  GPI-linked proteins  are 
capable of signal transduction as has been shown for several 
proteins  including NCA-95 (44, 45). Other CEA family mem- 
bers that are also often coexpressed with CEA, NCA, and 
CGM2, i.e. splice variants of BGP (46 and  data not shown), 
represent  integral  membrane proteins. That BGP  may  be in- 
volved in signal transduction  has been shown for the rat BGP 
homologue, which becomes tyrosine  phosphorylated in  the cy- 
toplasmic domain through  the  insulin receptor  tyrosine kinase 
(47). It  has also been demonstrated  that  human BGP is tyrosine 
phosphorylated  (48), a characteristic  that  suggests its role in 
signal transduction.  The existence of  CEA family member com- 
plexes could combine the adhesive  properties already reported 
for various family members (20-22, 49) with signal transduc- 
tion, either  through  the GPI-linked  members, through  the  in- 
tegral  membrane proteins, or through a combination of both. 
The down-regulation of the CGM2 gene expression at the 
transcriptional level in colonic adenocarcinomas as compared 
with  the  adjacent mucosa is similar  to  the down-regulation of 
the BGP gene  (17, 18), which indicates a potential tumor  sup- 
pressor function of these genes.  Indeed, it has recently been 
shown through transfection of  cDNAs for the rat BGP counter- 
part cellCAMlO5, into  tumor cell lines,  that  the  tumor pheno- 
type  is s~ppres sed .~  On the  other  hand, some members of the 
CEA-family are up-regulated in  tumors, e.g. NCA at the  tran- 
scriptional level (17,50)  and CEA at the protein level (51). This 
differential expression of closely related cell adhesion mol- 
ecules could play  a  direct role in  either suppression or stimu- 
lation of tumorigenesis  and/or progression. Down-regulation of 
other adhesion molecules has been implicated in  tumor pro- 
gression, e.g. E-cadherin (23)  or  the DCC gene product,  a  pu- 
tative adhesion molecule (24). Alternatively, overexpression of 
CEA in  rodent cells has been  shown to  enhance liver metasta- 
ses formation in athymic nude mice (52). 
There  are two possible explanations for the  identity of the 
3.2-kb mRNA species that is only seen  in  tumors (Fig. 5 A ) .  
First, a de novo low level expression of a new CEA-like gene 
J .  Thompson,  H.-J. Weig, and W. Zimmerman,  manuscript in  prep- 
F. Grunert,  personal  communication. 
S.-H. Lin, personal  communication. 
aration. 
could occur, as detected through cross-hybridization using  the 
CGMS probe. Due to  the lack of cross-hybridization with  other 
family  members known to be coexpressed in colonic mucosa, it 
would follow that this mRNA species must  have a higher se- 
quence similarity  to CGM2 than  to  other family members. Sec- 
ond, as down-regulation of CGM2 expression occurs in colorec- 
tal cancers, an  alternatively spliced CGM2  mRNA species could 
be expressed. Although alternative splicing of mRNAs coding 
for members of the CEA gene family has been found (4), to date 
it has not been  reported to occur as a cancer-specific phenom- 
enon. In  the case of the cell adhesion molecule CD44, tumor- 
specific splice variants have been demonstrated to promote 
metastasis (53). 
In  the  future, it will be of interest  to  study  the  putative role 
of the CGMB protein in mediating cell adhesion and signal 
transduction or its ability to build molecular complexes with 
other CEA family members. Experiments  are now underway  to 
see whether overexpression of the CGMS protein can  suppress 
the  malignant phenotype and  to  test for loss of heterozygosity 
and  mutations  in  the CGM2 gene locus of cancer patients. 
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